Ampio Pharmaceuticals (AMPE) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ampio Pharmaceuticals, Inc. has announced the successful completion of its recent nonclinical studies in a press release dated February 14, 2024. The company emphasizes that the information provided should not be considered part of the formal financial filings required by the SEC, but it serves to keep investors informed about its latest research developments.
For further insights into AMPE stock, check out TipRanks’ Stock Analysis page.